TMDX · Investment summary · as of 12 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · scaling but economically observable
At $89.36, TMDX requires a 23% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 26%.
Growth is demonstrated above requirement at every admissible exit; the disputed parameter is whether the investment-phase margin returns to the FY2025 level. The disagreement with the market is a margin story.
The value rests on an exit multiple of 15.1x, a terminal operating margin of 15% and a 8.2% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: The funding squeeze, unchanged in structure, improved in inputs: TransMedics must cover ~$895m inside 24 months (Somerville purchase option $374.6m - now scheduled by the company inside twelve months; converts $460.0m face due 1 June 2028, self-liquidating only above $94.00 vs spot $89.36; CIBC $59.7m amortising to Jul-2027) against $472.7m cash, FY2025 FCF of $133.6m and NEGATIVE 1H-2026 FCF (-$1.9m).
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Growth is demonstrated above requirement at every admissible exit; the disputed parameter is whether the investment-phase margin returns to the FY2025 level. The disagreement with the market is a margin story. |
| What do we forecast? | Revenue growth of 26% demonstrated; a terminal operating margin of 15%; an exit multiple of 15.1x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On terminal margin, the difference between what the price requires and what the business has demonstrated is +1.6 percentage points. |
| What is it worth? | Twelve-month target $122.80, +37% from the struck price. Scenario-weighted expected return net of costs +37.4%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| any 2026 guidance event, first tested Q3-26 print (~late Oct 2026, unconfirmed) | FY2026 revenue guidance | Cut at or above $737m (the raised low end) | cut below $737m (the raised low end) |
| each 10-Q; Q1-26 was 7.6%, Q2-26 12.5% reset the count | GAAP operating margin | At or above 10% for two consecutive quarters | below 10% for two consecutive quarters |
| each 10-Q organ table; Q2-26 +27.7% | US Liver revenue growth | At or above 20% YoY in any quarter | below 20% YoY in any quarter |
| each 10-Q; Q2-26 59.6% | Blended gross margin | At or above 56% for two consecutive quarters | below 56% for two consecutive quarters |
The funding squeeze, unchanged in structure, improved in inputs: TransMedics must cover ~$895m inside 24 months (Somerville purchase option $374.6m - now scheduled by the company inside twelve months; converts $460.0m face due 1 June 2028, self-liquidating only above $94.00 vs spot $89.36; CIBC $59.7m amortising to Jul-2027) against $472.7m cash, FY2025 FCF of $133.6m and NEGATIVE 1H-2026 FCF (-$1.9m). The trigger is a growth miss: a guidance cut converts the CIBC revenue covenant (total net revenue >= 75% of the plan presented to CIBC) into a credit event and forces an equity raise into a drawdown. New since the prior memo: guidance low end RAISED to $737m, service GM +6.5pp, cash +$11m - and against that, capex running at 2x CFO, PAD consideration undisclosed, and the option payment pulled inside 12 months.
Estimated probability 20%, against the 28% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
Trim on approach to the $123 point target; above ~$145 (post-regime p90 NTM EV/Sales ~7.0x on consensus FY2027 revenue) the position exceeds its own multiple history's 90th percentile - trim regardless of narrative. On approach to the $122.80 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Not determined | Can the intended position be built and exited in the right vehicle? Not established on the evidence on file. |
| Downside | Met | The funding squeeze, unchanged in structure, improved in inputs: TransMedics must cover ~$895m inside 24 months (Somerville purchase option $374.6m - now scheduled by the company inside twelve months; converts $460.0m face due 1 June 2028, self-liquidating only above $94.00 vs spot $89.36; CIBC $59.7m amortising to Jul-2027) against $472.7m cash, FY2025 FCF of $133.6m and NEGATIVE 1H-2026 FCF (-$1.9m). |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +1.6 percentage points more growth than the price requires. The most important unresolved uncertainty is whether a position could be built and exited at the intended size. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $76.50, which forces an immediate review.